COVID-19 vaccine for lung cancer patients
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing how well the COVID-19 vaccine works for people with lung cancer to prevent another infection. It also looks at certain biomarkers in your blood that might help predict your body's immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have lung cancer confirmed by a tissue or cell sample.
- You are currently getting cancer treatment like chemotherapy, immunotherapy, or targeted therapy.
- You have had COVID-19 at least once in the past.
- Your last COVID-19 infection was more than 3 months ago.
- You are not allergic to COVID-19 vaccines and have a life expectancy of more than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a new treatment called LK101 combined with a PD-1 or PD-L1 antibody for advanced lung cancer. It may help shrink tumors and improve control of the disease, especially after prior anti–PD-1/PD-L1 treatment has stopped working.
This trial tests a new treatment combining a dendritic cell vaccine (a type of immune therapy that trains your body to fight cancer) with additional immunotherapy drugs. It is for people with advanced lung cancer that has stopped responding to standard immunotherapy.
This trial tests a personalized immune cell therapy for advanced or relapsed lung cancer. Doctors take your blood, create special T cells that target unique proteins on your cancer, and give them back to you to try to fight the tumor.
This study looks at whether a pneumonia vaccine can help people with lung cancer. You can join no matter what stage your cancer is or what treatments you've had, as long as you haven't had this vaccine before.
This study monitors how the heart and lungs respond to radiation therapy combined with immunotherapy for locally advanced lung cancer. It aims to learn how well patients tolerate treatment and to detect early signs of side effects.
This trial is looking at how well a lung cancer treatment improves survival. It enrolls adults with confirmed lung cancer who can safely take the study medicines and have cancer that can be measured on scans.
Hear when a new COVID-19 Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.